Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Phathom Pharmaceuticals Inc (NQ: PHAT )

9.450 +0.720 (+8.25%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,098,131
Open 8.670
Bid (Size) 8.890 (15)
Ask (Size) 9.600 (1)
Prev. Close 8.730
Today's Range 8.610 - 9.620
52wk Range 6.065 - 19.71
Shares Outstanding 43,614,075
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire

Performance

YTD
+3.05%
+3.05%
1 Month
-43.04%
-43.04%
3 Month
-26.23%
-26.23%
6 Month
-8.25%
-8.25%
1 Year
+35.19%
+35.19%

More News

Read More
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting
From Phathom Pharmaceuticals
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
These Are The Top 3 Most-Shorted Stocks In August 2024; Here’s Why
Via Talk Markets
Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants
From Phathom Pharmaceuticals
Via GlobeNewswire
PHAT Stock Earnings: Phathom Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults
From Phathom Pharmaceuticals
Via GlobeNewswire
Ready for Quick Gains? 7 Top Short-Squeeze Stocks to Watch Now
Via InvestorPlace
Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze
Via InvestorPlace
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting
From Phathom Pharmaceuticals
Via GlobeNewswire
The 3 Best Healthcare Stocks to Buy in May 2024
Via InvestorPlace
PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
From Phathom Pharmaceuticals
Via GlobeNewswire
PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.